Supporting Information

S-nitrosothiols loaded mini-sized Au@silica nanorod elicits collagen

depletion and mitochondrial damage in solid tumor treatment

Ping Liu¹, Yidan Wang¹, Yang Liu³, Fengping Tan¹, Jining Li² and Nan Li¹

- Tianjin Key Laboratory of Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, 300072, Tianjin, P. R. China.
- 2. School of Precision Instrument and Opto-Electronics Engineering, Tianjin University, 300072, Tianjin, P. R. China.
- Department of Orthopedic Surgery, Tianjin Medical University General Hospital, 300052, Tianjin, P. R. China

Corresponding authors: Email: <u>linan19850115@163.com</u> (N. Li);
jiningli@tju.edu.cn (J. Li).



Figure S1. Standard curve of NaNO₂ standard samples (0-100 μ M).



Figure S2. FTIR spectra of GSN (black), GSP (red), GSNP (blue) and GSNP-TPP (green).



Figure S3. EDS spectra of GSNP-TPP.



Figure S4. Elemental mapping analysis of S and N in GSNP-TPP.



Figure S5. Confocal microscopy images of HeLa cells treated with saline, GSNPs and GSNP-TPPs. GSNPs and GSNP-TPPs were labeled with ZnPc and emitted red fluorescence. Mitochondria were stained by 50 nM Mito-Tracker Green and emitted green fluorescence. Scale bar indicated 25 μ m.



Figure S6. Statistical assay of JC-1 monomer/aggregate ratio shown in Figure 4G. I, II, III were indicated saline, GSP-TPPs+laser and GSNP-TPPs+laser, respectively. (n=3, *p < 0.05)



Figure S7. A) Cell viability of HeLa, 4T-1 and MCF-7 cells after treatment with various concentrations (0, 25, 50, 100 and 200 μ g/mL). B) Cell viability of H9c2 cells after treatment with various concentrations (0, 5, 12.5, 25, 50, 100 and 200 μ g/mL). C) Cell viability of HeLa cells after treatment with various

concentrations (0, 25, 50, 100 and 200 μ g/mL). (n=3, **p < 0.01)



Figure S8. In vitro hemolysis assay of GSNP-TPPs. Inset: hemolysis photos after centrifugation.



Figure S9. A-D, F) Statistical assay of p53, Bax, Bcl-2, Cleaved Caspase-3 and HSP90 contents according to their result of western blot. (n=3, **p < 0.01) E) Western blot of HSP90 with different treatment: I Control, II GSPs+laser, III GSNP-TPPs+laser.



Figure S10. Quantitative comparison of the green fluorescence intensity shown in Figure 4H. (n=3, *p < 0.05)



Figure S11. In vivo CT images of HeLa tumor-bearing mice after i.v. injection

of iopromide solution at different times (0, 1, 2, 6, 12, 24 h).



Figure S12. Represents the tumor weights in control (saline) and treatment (GSNP-TPPs+laser) groups after removal of the tumor from animals. Each point represents the weight of each tumor and the lines represent the mean value. "*" denotes statistical difference (**p < 0.01).



Figure S13. TUNEL assay, immunohistochemical and immunofluorescent staining of tumor sections from GSP-TPPs+laser and GSNP-TPPs+uric acid+laser groups. Immunohistochemical staining for MMP-1, MMP-2 and 3-NT proteins. Immunofluorescent staining for Collagen I and 3-NT.



Figure S14. Quantification of the percentage of apoptotic cells in the TUNEL assay in Figure 7 and S13. I Control, II GSP-TPPs+laser, III GSNP-TPPs+laser, IV GSNP-TPPs+uric acid+laser. (n=5, **p < 0.01)



Figure S15. Immunohistochemical staining of tumor tissues for HSP90 and Ki67 proteins.

in western bioliting			
Antibody	Brand	Catalog	Dilution
		number	
p53	Solarbio	K101293P	1: 500
Bcl-2	Solarbio	K003505P	1: 1000
Bax	Solarbio	K001593P	1: 1200
Cleaved	SAB	29034	1. 1200
Caspase-3		20004	1. 1200
HSP90	Solarbio	K106929P	1: 500
MMP-1	Solarbio	K000342P	1: 500
MMP-2	Solarbio	K101302P	1: 500
GAPDH	Solarbio	K200057M	1: 1000

Table S1. The brand, catalog number and the dilution for each antibody used

in western blotting